The Journal of Nutritional Biochemistry
Volume 21, Issue 9 , Pages 841-847 , September 2010

Daidzein and the daidzein metabolite, equol, enhance adipocyte differentiation and PPARγ transcriptional activity

  • Kae Won Cho

      Affiliations

    • Department of Nutrition, University of Massachusetts, Amherst, MA 01003, USA
    • ,
  • Ok-Hwan Lee

      Affiliations

    • Department of Nutrition, University of Massachusetts, Amherst, MA 01003, USA
    • ,
  • William J. Banz

      Affiliations

    • Department of Nutrition and Animal Science, Southern Illinois University, Carbondale, IL 62901, USA
    • ,
  • Naima Moustaid-Moussa

      Affiliations

    • Department of Animal Science and UT Obesity Research Center, The University of Tennessee, Knoxville, TN, 37996, USA
    • ,
  • Neil F. Shay

      Affiliations

    • Department of Food Science and Nutrition, University of Florida, FL, 32611, USA
    • ,
  • Young-Cheul Kim

      Affiliations

    • Department of Nutrition, University of Massachusetts, Amherst, MA 01003, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 413 577 4553; fax: +1 413 545 1074.

Received 15 December 2008 ,Revised 20 March 2009 ,Accepted 23 June 2009.

References 

  1. Olefsky JM, Ciaraldi TP, Kolterman OG. Mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes. Am J Med. 1985;79:12–22
  2. Olefsky JM, Nolan JJ. Insulin resistance and non-insulin-dependent diabetes mellitus: cellular and molecular mechanisms. Am J Clin Nutr. 1995;61:980S–986S
  3. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001;109:S135–S148
  4. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787
  5. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195–1200
  6. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care. 2000;23:1278–1283
  7. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev. 2003;14:447–455
  8. Melby MK, Murashima M, Watanabe S. Phytochemical intake and relationship to past health history in Japanese women. Biofactors. 2004;22:265–269
  9. Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in Type 2 diabetic subjects. Diabetes Care. 2001;24:228–233
  10. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276–282
  11. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr. 2003;133:1238–1243
  12. Davis J, Higginbotham A, O'Connor T, Moustaid-Moussa N, Tebbe A, Kim YC, et al. Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat. Ann Nutr Metab. 2007;51:42–52
  13. Jayagopal V, Albertazzi P, Kilpatrick ES, Howarth EM, Jennings PE, Hepburn DA, et al. Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care. 2002;25:1709–1714
  14. Joffe BI, Panz VR, Raal FJ. From lipodystrophy syndromes to diabetes mellitus. Lancet. 2001;357:1379–1381
  15. Frayn KN. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc. 2001;60:375–380
  16. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003;14:137–145
  17. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001;409:729–733
  18. Resh MD. Development of insulin responsiveness of the glucose transporter and the (Na+,K+)-adenosine triphosphatase during in vitro adipocyte differentiation. J Biol Chem. 1982;257:6978–6986
  19. Cornelius P, MacDougald OA, Lane MD. Regulation of adipocyte development. Annu Rev Nutr. 1994;14:99–129
  20. Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci. U. S. A. 2000;97:11371–11376
  21. Jansson PA, Pellme F, Hammarstedt A, Sandqvist M, Brekke H, Caidahl K, et al. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J. 2003;17:1434–1440
  22. Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol. 2000;16:145–171
  23. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507–514
  24. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 2002;16:22–26
  25. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 1999;4:611–617
  26. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996;39:665–668
  27. Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996;137:4189–4195
  28. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest. 2000;106:1221–1228
  29. Kim YC, Gomez FE, Fox BG, Ntambi JM. Differential regulation of the stearoyl-CoA desaturase genes by thiazolidinediones in 3T3-L1 adipocytes. J Lipid Res. 2000;41:1310–1316
  30. Phillips M, Enan E, Liu PC, Matsumura F. Inhibition of 3T3-L1 adipose differentiation by 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Cell Sci. 1995;108:395–402
  31. Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W, et al. Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci. U. S. A. 2004;101:10703–10708
  32. Le Lay S, Lefrere I, Trautwein C, Dugail I, Krief S. Insulin and sterol-regulatory element-binding protein-1c (SREBP-1C) regulation of gene expression in 3T3-L1 adipocytes. Identification of CCAAT/enhancer-binding protein beta as an SREBP-1C target. J Biol Chem. 2002;277:35625–35634
  33. Gomez FE, Miyazaki M, Kim YC, Marwah P, Lardy HA, Ntambi JM, et al. Molecular differences caused by differentiation of 3T3-L1 preadipocytes in the presence of either dehydroepiandrosterone (DHEA) or 7-oxo-DHEA. Biochemistry. 2002;41:5473–5482
  34. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994;91:7355–7359
  35. Dang Z, Lowik CW. The balance between concurrent activation of ERs and PPARs determines daidzein-induced osteogenesis and adipogenesis. J Bone Miner Res. 2004;19:853–861
  36. Clarkson TB. Soy, soy phytoestrogens and cardiovascular disease. J Nutr. 2002;132:566S–569S
  37. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592–5595
  38. Setchell KD. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr. 1998;68:1333S–1346S
  39. Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA. The variable metabolic response to dietary isoflavones in humans. Proc Soc Exp Biol Med. 1995;208:40–43
  40. Setchell KD, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005;81:1072–1079
  41. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr. 2001;131:1362S–1375S
  42. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002;132:3577–3584
  43. El-Jack AK, Hamm JK, Pilch PF, Farmer SR. Reconstitution of insulin-sensitive glucose transport in fibroblasts requires expression of both PPARgamma and C/EBPalpha. J Biol Chem. 1999;274:7946–7951
  44. Czech MP. Molecular actions of insulin on glucose transport. Annu Rev Nutr. 1995;15:441–471
  45. Harmon AW, Patel YM, Harp JB. Genistein inhibits CCAAT/enhancer-binding protein beta (C/EBPbeta) activity and 3T3-L1 adipogenesis by increasing C/EBP homologous protein expression. Biochem J. 2002;367:203–208
  46. Zhang M, Ikeda K, Xu JW, Yamori Y, Gao X-M, Zhang B-L. Genistein suppresses adipogenesis of 3T-L1 cells via multiple signal pathways. Phytother Res. 2008;
  47. Watanabe S, Yamaguchi M, Sobue T, Takahashi T, Miura T, Arai Y, et al. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr. 1998;128:1710–1715
  48. Izumi T, Piskula MK, Osawa S, Obata A, Tobe K, Saito M, et al. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J Nutr. 2000;130:1695–1699

PII: S0955-2863(09)00136-3

doi: 10.1016/j.jnutbio.2009.06.012

The Journal of Nutritional Biochemistry
Volume 21, Issue 9 , Pages 841-847 , September 2010

Article Tools

* Image Usage & Resolution